ibi321

mAbexperimentalBi-specific

Clinical trial activity

3 trials · 1 clinical orgs · 0 marketing orgs

Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0

Earliest trial started Jul 1, 2021 (NCT04911881)

Timeline

2020s

  1. Jan 1, 2021

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Multi-specific
Yes (Bi-specific)

Oral

No

Parenteral

No

Topical

No

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05172856Phase 1Mar 1, 2022Innovent Biologics (Suzhou) Co. Ltd.
NCT04911894Phase 1Jul 16, 2021Innovent Biologics (Suzhou) Co. Ltd.
NCT04911881Phase 1Jul 1, 2021Innovent Biologics (Suzhou) Co. Ltd.
Showing 3 of 3 trials
Page 1 / 1

Organizations

Research & Development (1)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Innovent Biologics (Suzhou) Co. Ltd.For profit3312021
1 organizations
Page 1 / 1